Medical Condition News

RSS

WHO DG Chan says media allegations of agency receiving food industry funding to fight NCDs 'wrong'

In a statement released on Monday, WHO Director-General Margaret Chan said "[s]everal recent media articles are creating misinformation and confusion in the public health arena" by "erroneously suggesting that, in working to reduce non-communicable diseases (NCDs) such as cardiovascular diseases, cancers, chronic respiratory diseases and diabetes, WHO receives funding from the food and beverage industry," the U.N. News Centre reports.

21 Nov 2012

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that its selective histone deacetylase (HDAC) inhibitors will be featured in five posters and one oral presentation at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place December 8-11, 2012, in Atlanta, Georgia.

21 Nov 2012

Sharp decline in ECT availability and use in the U.S. general hospitals

Electroconvulsive therapy (ECT) is considered the most effective treatment option for patients with severe depression who cannot find symptom relief through antidepressant medications or psychotherapy. In a new study, researchers at Butler Hospital and Bradley Hospital in Rhode Island found a sharp decline in the availability and use of ECT in general hospitals across the U.S.

21 Nov 2012

Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed a long-term license agreement with Fujirebio Inc. to make its biomarker assay Procalcitonin (PCT) available on the Lumipulse family of laboratory instruments, using the chemiluminescent enzyme immunoassay (CLEIA) technology.

From Thermo Fisher Scientific Inc. 21 Nov 2012

Musical tones can reset the brain and effectively reduce insomnia

If you are among the 50 percent of Americans who suffer from insomnia, then you have probably tried everything – from warm milk to melatonin pills or prescription medications to induce sleep – with varying degrees of success and side effects. But what if sleep could be achieved not by a substance, but through 'balancing' brain activity?

21 Nov 2012

Young girls can dance their way to better mental health

Young girls can dance their way to better mental health. Symptoms like depression, stress, fatigue, and headaches are alleviated with regular dancing.

21 Nov 2012

UMDNJ, Proteonomix commence screening of patients with ESLD for use in UMK-121 clinical trial

PROTEONOMIX, INC., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the University of Medicine & Dentistry of New Jersey (UMDNJ) in conjunction with the Company has commenced the screening of patients with End Stage Liver Disease (ESLD) for use in its clinical trial of UMK-121.

21 Nov 2012

MRI reveals changes in brains of people with post-concussion syndrome

MRI shows changes in the brains of people with post-concussion syndrome (PCS), according to a new study published online in the journal Radiology. Researchers hope the results point the way to improved detection and treatment for the disorder.

21 Nov 2012

Scientists extract recent drug trials to tackle Alzheimer's earlier than ever before

Alzheimer's therapeutic trials have gotten bad press lately, but it is not all gloom and doom. As evident at the 5th Clinical Trials in Alzheimer's Disease (CTAD) conference, held 29-31 October in the Principality of Monaco, scientists keep extracting new data from recent drug trials to gear up for a round of new ones that aim to tackle Alzheimer's earlier than ever before.

21 Nov 2012

TAU researcher connects computer communications and psychosis

As Internet access becomes increasingly widespread, so do related psychopathologies such as Internet addiction and delusions related to the technology and to virtual relationships. Computer communications such as Facebook and chat groups are an important part of this story, says Dr. Uri Nitzan of Tel Aviv University's Sackler Faculty of Medicine and the Shalvata Mental Health Care Center in a new paper published in the Israel Journal of Psychiatry and Related Sciences.

21 Nov 2012

HeartWare receives FDA approval for new left ventricular assist device

The U.S. Food and Drug Administration today approved the HeartWare Ventricular Assist System, a left ventricular assist device (LVAD), to support heart function and blood flow in patients with end-stage heart failure who are awaiting a heart transplant.

21 Nov 2012

Certain mutated cells continue DNA replication process even after drug treatment

Certain mutated cells keep trying to replicate their DNA - with disastrous results - even after medications rob them of the raw materials to do so, according to new research from USC.

21 Nov 2012

IUD insertion does not increase risk of pelvic inflammatory disease in women

The risk of developing pelvic inflammatory disease (PID) following insertion of an intrauterine device (IUD) is very low, whether or not women have been screened beforehand for gonorrhea and chlamydia, according to a joint study of nearly 60,000 women by researchers at the University of California, San Francisco (UCSF), and Kaiser Permanente Northern California Division of Research.

21 Nov 2012

Novel test reveals rate of progression of amyotrophic lateral sclerosis in patients

A novel test that measures proteins from nerve damage that are deposited in blood and spinal fluid reveals the rate of progression of amyotrophic lateral sclerosis (ALS) in patients, according to researchers from Mayo Clinic's campus in Florida, Emory University and the University of Florida.

21 Nov 2012

Novel technology can lead to more efficient and cheaper therapy for Pompe disease

VIB researchers from UGent and Vrije Universiteit Brussel , together with a team of the firm Oxyrane have developed a new technology that can lead to a more efficient and possibly also cheaper therapy for diseases such as Pompe disease. Oxyrane will now start developing a clinical program for this therapy in Pompe disease.

21 Nov 2012

Only 3% of patients actually receive stress management counseling: Study

While stress may be a factor in 60 to 80 percent of all visits to primary care physicians, only three percent of patients actually receive stress management counseling, say researchers at Beth Israel Deaconess Medical Center.

21 Nov 2012

NeuroDerm initiates enrollment in ND0612 Phase I trial for Parkinson's

NeuroDerm, Ltd. announced today that enrollment of healthy subjects is ongoing in its Phase I clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously via a subcutaneous delivery patch device. It is designed to provide steady levodopa blood levels and enhanced bioavailability of oral levodopa for the reduction of motor complications in Parkinson's disease.

21 Nov 2012

Lupin’s Fenofibrate tablets now available in the U.S.

Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has launched its Fenofibrate Tablets, 48 mg and 145 mg strengths in the United States. Lupin had earlier received final approval for the same from the US Food and Drug Administration (FDA).

21 Nov 2012

Small non-coding RNA715 plays an important role in regulating myelin formation in the CNS

Scientists at the Mainz University Medical Center have discovered another molecule that plays an important role in regulating myelin formation in the central nervous system.

21 Nov 2012

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

Bristol-Myers Squibb and Pfizer announced today that the European Commission has approved ELIQUIS (apixaban) for prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors.

21 Nov 2012

Medical Condition News

WHO DG Chan says media allegations of agency receiving food industry funding to fight NCDs 'wrong'

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Sharp decline in ECT availability and use in the U.S. general hospitals

Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing

Musical tones can reset the brain and effectively reduce insomnia

Young girls can dance their way to better mental health

UMDNJ, Proteonomix commence screening of patients with ESLD for use in UMK-121 clinical trial

MRI reveals changes in brains of people with post-concussion syndrome

Scientists extract recent drug trials to tackle Alzheimer's earlier than ever before

TAU researcher connects computer communications and psychosis

HeartWare receives FDA approval for new left ventricular assist device

Certain mutated cells continue DNA replication process even after drug treatment

IUD insertion does not increase risk of pelvic inflammatory disease in women

Novel test reveals rate of progression of amyotrophic lateral sclerosis in patients

Novel technology can lead to more efficient and cheaper therapy for Pompe disease

Only 3% of patients actually receive stress management counseling: Study

NeuroDerm initiates enrollment in ND0612 Phase I trial for Parkinson's

Lupin’s Fenofibrate tablets now available in the U.S.

Small non-coding RNA715 plays an important role in regulating myelin formation in the CNS

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Latest News